基于SVM和平均影响值的人肿瘤信息基因提取

基于基因表达谱的肿瘤分类信息基因选取是发现肿瘤特异表达基因、探索肿瘤基因表达模式的重要手段。借助由基因表达谱获得的分类信息进行肿瘤诊断是当今生物信息学领域中的一个重要研究方向,有望成为临床医学上一种快速而有效的肿瘤分子诊断方法。鉴于肿瘤基因表达谱样本数据维数高、样本量小以及噪音大等特点,提出一种结合支持向量机应用平均影响值来寻找肿瘤信息基因的算法,其优点是能够搜索到基因数量尽可能少而分类能力尽可能强的多个信息基因子集。采用二分类肿瘤数据集验证算法的可行性和有效性,对于结肠癌样本集,只需3个基因就能获得100%的留一法交叉验证识别准确率。为避免样本集的不同划分对分类性能的影响,进一步采用全折交叉验证方法来评估各信息基因子集的分类性能,优选出更可靠的信息基因子集。与基它肿瘤分类方法相比,实验结果在信息基因数量以及分类性能方面具有明显的优势。     

Computational methods for gene expression-based tumor classification

Gene expression profiles may offer more or additional information than classic morphologic- and histologic-based tumor classification systems. Because the number of tissue samples examined is usually much smaller than the number of genes examined, efficient data reduction and analysis methods are critical. In this report, we propose a principal component and discriminant analysis method of tumor classification using gene expression profile data. Expression of 2000 genes in 40 tumor and 22 normal colon tissue samples is used to examine the feasibility of gene expression-based tumor classification systems. Using this method, the percentage of correctly classified normal and tumor tissue was 87.0%. The combined approach using principal components and discriminant analysis provided superior sensitivity and specificity compared to an approach using simple differences in the expression levels of individual genes.     

Non-linear cancer classification using a modified radial basis function classification algorithm

Summary This paper proposes a modified radial basis function classification algorithm for non-linear cancer classification. In the algorithm, a modified simulated annealing method is developed and combined with the linear least square and gradient paradigms to optimize the structure of the radial basis function (RBF) classifier. The proposed algorithm can be adopted to perform non-linear cancer classification based on gene expression profiles and applied to two microarray data sets involving various human tumor classes: (1) Normal versus colon tumor; (2) acute myeloid leukemia (AML) versus acute lymphoblastic leukemia (ALL). Finally, accuracy and stability for the proposed algorithm are further demonstrated by comparing with the other cancer classification algorithms.     

Class discovery and classification of tumor samples using mixture modeling of gene expression data--a unified approach

MOTIVATION: The DNA microarray technology has been increasingly used in cancer research. In the literature, discovery of putative classes and classification to known classes based on gene expression data have been largely treated as separate problems. This paper offers a unified approach to class discovery and classification, which we believe is more appropriate, and has greater applicability, in practical situations. RESULTS: We model the gene expression profile of a tumor sample as from a finite mixture distribution, with each component characterizing the gene expression levels in a class. The proposed method was applied to a leukemia dataset, and good results are obtained. With appropriate choices of genes and preprocessing method, the number of leukemia types and subtypes is correctly inferred, and all the tumor samples are correctly classified into their respective type/subtype. Further evaluation of the method was carried out on other variants of the leukemia data and a colon dataset.     

Gene selection for sample classification based on gene expression data: study of sensitivity to choice of parameters of the GA/KNN method.

MOTIVATION: We recently introduced a multivariate approach that selects a subset of predictive genes jointly for sample classification based on expression data. We tested the algorithm on colon and leukemia data sets. As an extension to our earlier work, we systematically examine the sensitivity, reproducibility and stability of gene selection/sample classification to the choice of parameters of the algorithm. METHODS: Our approach combines a Genetic Algorithm (GA) and the k-Nearest Neighbor (KNN) method to identify genes that can jointly discriminate between different classes of samples (e.g. normal versus tumor). The GA/KNN method is a stochastic supervised pattern recognition method. The genes identified are subsequently used to classify independent test set samples. RESULTS: The GA/KNN method is capable of selecting a subset of predictive genes from a large noisy data set for sample classification. It is a multivariate approach that can capture the correlated structure in the data. We find that for a given data set gene selection is highly repeatable in independent runs using the GA/KNN method. In general, however, gene selection may be less robust than classification. AVAILABILITY: The method is available at http://dir.niehs.nih.gov/microarray/datamining CONTACT: LI3@niehs.nih.gov     

Tissue classification with gene expression profiles.

Constantly improving gene expression profiling technologies are expected to provide understanding and insight into cancer-related cellular processes. Gene expression data is also expected to significantly aid in the development of efficient cancer diagnosis and classification platforms. In this work we examine three sets of gene expression data measured across sets of tumor(s) and normal clinical samples: The first set consists of 2,000 genes, measured in 62 epithelial colon samples (Alon et al., 1999). The second consists of approximately equal to 100,000 clones, measured in 32 ovarian samples (unpublished extension of data set described in Schummer et al. (1999)). The third set consists of approximately equal to 7,100 genes, measured in 72 bone marrow and peripheral blood samples (Golub et al, 1999). We examine the use of scoring methods, measuring separation of tissue type (e.g., tumors from normals) using individual gene expression levels. These are then coupled with high-dimensional classification methods to assess the classification power of complete expression profiles. We present results of performing leave-one-out cross validation (LOOCV) experiments on the three data sets, employing nearest neighbor classifier, SVM (Cortes and Vapnik, 1995), AdaBoost (Freund and Schapire, 1997) and a novel clustering-based classification technique. As tumor samples can differ from normal samples in their cell-type composition, we also perform LOOCV experiments using appropriately modified sets of genes, attempting to eliminate the resulting bias. We demonstrate success rate of at least 90% in tumor versus normal classification, using sets of selected genes, with, as well as without, cellular-contamination-related members. These results are insensitive to the exact selection mechanism, over a certain range.     

Tumor classification by partial least squares using microarray gene expression data

MOTIVATION: One important application of gene expression microarray data is classification of samples into categories, such as the type of tumor. The use of microarrays allows simultaneous monitoring of thousands of genes expressions per sample. This ability to measure gene expression en masse has resulted in data with the number of variables p(genes) far exceeding the number of samples N. Standard statistical methodologies in classification and prediction do not work well or even at all when N < p. Modification of existing statistical methodologies or development of new methodologies is needed for the analysis of microarray data. RESULTS: We propose a novel analysis procedure for classifying (predicting) human tumor samples based on microarray gene expressions. This procedure involves dimension reduction using Partial Least Squares (PLS) and classification using Logistic Discrimination (LD) and Quadratic Discriminant Analysis (QDA). We compare PLS to the well known dimension reduction method of Principal Components Analysis (PCA). Under many circumstances PLS proves superior; we illustrate a condition when PCA particularly fails to predict well relative to PLS. The proposed methods were applied to five different microarray data sets involving various human tumor samples: (1) normal versus ovarian tumor; (2) Acute Myeloid Leukemia (AML) versus Acute Lymphoblastic Leukemia (ALL); (3) Diffuse Large B-cell Lymphoma (DLBCLL) versus B-cell Chronic Lymphocytic Leukemia (BCLL); (4) normal versus colon tumor; and (5) Non-Small-Cell-Lung-Carcinoma (NSCLC) versus renal samples. Stability of classification results and methods were further assessed by re-randomization studies.     

Prediction and uncertainty in the analysis of gene expression profiles

We have developed a complete statistical model for the analysis of tumor specific gene expression profiles. The approach provides investigators with a global overview on large scale gene expression data, indicating aspects of the data that relate to tumor phenotype, but also summarizing the uncertainties inherent in classification of tumor types. We demonstrate the use of this method in the context of a gene expression profiling study of 27 human breast cancers. The study is aimed at defining molecular characteristics of tumors that reflect estrogen receptor tatus. In addition to good predictive performance with respect to pure classification of the expression profiles, the model also uncovers conflicts in the data with respect to the classification of some of the tumors, highlighting them as critical cases for which additional investigations are appropriate.     

Gene mining: a novel and powerful ensemble decision approach to hunting for disease genes using microarray expression profiling

Current applications of microarrays focus on precise classification or discovery of biological types, for example tumor versus normal phenotypes in cancer research. Several challenging scientific tasks in the post-genomic epoch, like hunting for the genes underlying complex diseases from genome-wide gene expression profiles and thereby building the corresponding gene networks, are largely overlooked because of the lack of an efficient analysis approach. We have thus developed an innovative ensemble decision approach, which can efficiently perform multiple gene mining tasks. An application of this approach to analyze two publicly available data sets (colon data and leukemia data) identified 20 highly significant colon cancer genes and 23 highly significant molecular signatures for refining the acute leukemia phenotype, most of which have been verified either by biological experiments or by alternative analysis approaches. Furthermore, the globally optimal gene subsets identified by the novel approach have so far achieved the highest accuracy for classification of colon cancer tissue types. Establishment of this analysis strategy has offered the promise of advancing microarray technology as a means of deciphering the involved genetic complexities of complex diseases.     

基因表达数据小波降噪与肿瘤识别

建立了基于小波降噪和支持向量机的结肠癌基因表达数据肿瘤识别模型.对试验数据进行小波分解,并利用交叉验证的方法计算试验样本的平均分类准确率,确定小波函数与小波分解层数;引入能量阈值方法对小波分解系数进行阈值处理,达到降噪的目的;提出了基因分类贡献率与主成分分析结合的方法,提取结肠癌样本数据特征;利用支持向量机强大的非线性映射能力,实现对结肠癌样本数据的非线性分类.为了减弱样本集的划分对分类准确率的影响,本文采取Jackknife检验方法对支持向量分类器的分类器检验,其分类准确率为96.77%.试验结果证明了该方法的有效性,该方法对结肠癌的识别具有一定的参考价值.     

Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice

NK4, originally prepared as a competitive antagonist for hepatocyte growth factor (HGF), is a bifunctional molecule that acts as an HGF-antagonist and angiogenesis inhibitor. When the expression plasmid for NK4 gene was administered into mice by hydrodynamics-based delivery, the repetitive increase in the plasma NK4 protein level was achieved by repetitive administration of NK4 gene. Mice were subcutaneously implanted with colon cancer cells and weekly given with the NK4 plasmid. The repetitive delivery and expression of NK4 gene inhibited angiogenesis and invasiveness of colon cancer cells in subcutaneous tumor tissue and this was associated with suppression of primary tumor growth. By fifty days after tumor implantation, cancer cells naturally metastasized to the liver, whereas NK4 gene expression potently inhibited liver metastasis. Inhibition of the HGF-Met receptor pathway and tumor angiogenesis by NK4 gene expression has potential therapeutic value toward inhibition of invasion, growth, and metastasis of colon cancer.     

The clinical impact of miRNA34a and P53 gene expression in colon cancer

ObjectiveTo study the potential role of miRNA34a gene expression and its relationship with P53 gene expression, fate, stage, metastasis and overall survival of colorectal cancer.Patients and methodsThis study was carried out 30 patients with colon adenocarcinoma, 30 patients with benign colon polyp and 30 apparently healthy persons served as controls. All participants were subjected to full history taking, general clinical examination. Complete blood count, liver and kidney function, determination of serum tumor markers were done. Estimation of microRNA 34a and P53 Gene expression by real-time PCR were done.ResultsThere was a significant negative relationship between serum tumor markers and micro RNA 34a gene expression in cancer patients. Also, there was a statistically significant positive relationship between miRNA34a gene expression and P53 gene expression in both patients groups. The diagnostic accuracy of miRNA34a gene expression was both sensitive and specific for colon cancer. MiRNA34a and P53 gene expression had statistically significant relation with tumor stage and presence of metastases.ConclusionIt can be concluded that the level of miRNA34a can be used to differentiate between colon cancers and begin adenomas. MiRNA34a can be used as a prognostic marker in colon cancer.     

Colon cancer prediction with genetic profiles using intelligent techniques

Micro array data provides information of expression levels of thousands of genes in a cell in a single experiment. Numerous efforts have been made to use gene expression profiles to improve precision of tumor classification. In our present study we have used the benchmark colon cancer data set for analysis. Feature selection is done using t‐statistic. Comparative study of class prediction accuracy of 3 different classifiers viz., support vector machine (SVM), neural nets and logistic regression was performed using the top 10 genes ranked by the t‐statistic. SVM turned out to be the best classifier for this dataset based on area under the receiver operating characteristic curve (AUC) and total accuracy. Logistic Regression ranks as the next best classifier followed by Multi Layer Perceptron (MLP). The top 10 genes selected by us for classification are all well documented for their variable expression in colon cancer. We conclude that SVM together with t-statistic based feature selection is an efficient and viable alternative to popular techniques.     

基于邻接矩阵分解的肿瘤亚型特征提取方法

基于肿瘤基因表达谱的肿瘤分类是生物信息学的一个重要研究内容。传统的肿瘤信息特征提取方法大多基于信息基因选择方法,但是在筛选基因时,不可避免的会造成分类信息的流失。提出了一种基于邻接矩阵分解的肿瘤亚型特征提取方法,首先对肿瘤基因表达谱数据构造高斯权邻接矩阵,接着对邻接矩阵进行奇异值分解,最后将分解得到的正交矩阵特征行向量作为分类特征输入支持向量机进行分类识别。采用留一法对白血病两个亚型的基因表达谱数据集进行实验,实验结果证明了该方法的可行性和有效性。     

Metasample-based sparse representation for tumor classification

A reliable and accurate identification of the type of tumors is crucial to the proper treatment of cancers. In recent years, it has been shown that sparse representation (SR) by l1-norm minimization is robust to noise, outliers and even incomplete measurements, and SR has been successfully used for classification. This paper presents a new SR-based method for tumor classification using gene expression data. A set of metasamples are extracted from the training samples, and then an input testing sample is represented as the linear combination of these metasamples by l1-regularized least square method. Classification is achieved by using a discriminating function defined on the representation coefficients. Since l1-norm minimization leads to a sparse solution, the proposed method is called metasample-based SR classification (MSRC). Extensive experiments on publicly available gene expression data sets show that MSRC is efficient for tumor classification, achieving higher accuracy than many existing representative schemes.     

S100A4基因在结肠癌中的表达及意义

目的：通过检测S100A4基因在结肠癌细胞系及结肠癌组织中的表达,探讨其与结肠癌的关系。方法：运用RT-PCR法检测不同结肠癌细胞系中S100A4基因的表达情况;通过原位杂交和免疫组化方法检测61例结肠癌标本中S100A4基因的表达。结果：结肠癌细胞系Lovo及HT29均有S100A4基因表达。S100A4蛋白和RNA在结肠癌中表达率分别为36．1％和34.4％,而在正常结肠组织中不表达（p〈0．05）。临床分期晚比临床分期早的患者S100A4表达明显增高（p〈0.05）;有淋巴结转移的患者比无淋巴结转移的患者S100A4表达明显增高（p〈0．05）。此外,S100A4表达还与肿瘤大小,病理学分级,肉眼分型等相关。结论：结肠癌中S100A4基因表达增高,而且与肿瘤的侵袭及转移密切相关,是判断结肠癌生物学行为及预后的有价值的指标。